Red Flags
- Acute urinary retention with renal impairment, infection, or significant distress — same-day catheterisation; investigate cause; trial without catheter on alpha-blocker[1]
- Macroscopic haematuria, suspected prostate cancer (raised PSA, abnormal DRE), or weight loss — separate cancer pathway[1]
- Recurrent UTI, bladder stones, refractory retention, hydronephrosis, or persistent residual >300 mL — surgical indication[1]
- Severe LUTS with renal impairment or acute on chronic retention — admit; avoid rapid decompression (post-obstructive diuresis); urology[1]
First-line treatment
Interventions
- Watchful waiting + lifestyle for mild symptoms[1]Reduce evening fluids, avoid caffeine and alcohol after evening, double voiding, bladder retraining, manage constipation; effective for IPSS ≤7
- Combination medical therapy for moderate-severe symptoms[1]Alpha-blocker for symptom relief; add 5-alpha-reductase inhibitor for prostates >30 mL or PSA >1.5 (slower progression, reduces retention/surgery); add antimuscarinic or beta-3 agonist for OAB component
- Minimally invasive surgical therapy (MIST)[1]Prostatic urethral lift (UroLift) — favours sexual function; water vapour thermal therapy (Rezum); aquablation; Optilume; outpatient or short-stay; selected based on prostate size and anatomy
- Standard surgical procedures[1]TURP — gold standard for prostates 30–80 mL. Holmium laser enucleation (HoLEP) — size-independent, lower bleeding. Photoselective vaporisation (GreenLight) — useful in anticoagulated. Simple prostatectomy (open or robotic) — large prostates >80–100 mL
First-line drug therapy
| Drug | Class | Adult | Paediatric | Notes |
|---|---|---|---|---|
| Tamsulosin or silodosin (alpha-blocker)[1] | Selective alpha-1A adrenergic blocker | Tamsulosin 0.4 mg PO daily; silodosin 8 mg PO daily | — | First-line symptomatic; rapid onset (days–weeks); orthostatic hypotension; intraoperative floppy iris syndrome — inform ophthalmologist before cataract surgery |
| Finasteride or dutasteride (5-ARI)[1] | 5-alpha-reductase inhibitor | Finasteride 5 mg PO daily; dutasteride 0.5 mg PO daily | — | Add to alpha-blocker for prostate >30 mL or PSA >1.5; takes 6–12 months for full effect; reduces PSA by ~50% (interpret cancer screening accordingly); sexual side effects; teratogen — avoid handling crushed tablets in pregnancy |
| Combination alpha-blocker + 5-ARI (Combodart, Jalyn)[1] | Combination | Tamsulosin 0.4 mg + dutasteride 0.5 mg PO daily | — | Convenient single-pill combination; CombAT trial showed superior symptom and progression outcomes |
| Tadalafil 5 mg (LUTS + ED)[1] | PDE5 inhibitor | 5 mg PO once daily | — | Daily-dose tadalafil approved for combined LUTS and ED; do not combine with nitrates; useful when sexual function preservation prioritised |
| Antimuscarinic (solifenacin, tolterodine) for OAB component[1] | Muscarinic antagonist | Solifenacin 5–10 mg PO daily; tolterodine ER 4 mg PO daily | — | Add for OAB symptoms (urgency, frequency, nocturia) when residual urine acceptable; check PVR before adding (caution if >150 mL); dry mouth, constipation |
| Mirabegron (beta-3 agonist) for OAB component[1] | Beta-3 agonist | 25–50 mg PO daily | — | Alternative to antimuscarinic; lower dry mouth burden; BP elevation; less anticholinergic side effects |
Tamsulosin or silodosin (alpha-blocker)[1]
Selective alpha-1A adrenergic blocker
- Adult
- Tamsulosin 0.4 mg PO daily; silodosin 8 mg PO daily
- Paediatric
- —
First-line symptomatic; rapid onset (days–weeks); orthostatic hypotension; intraoperative floppy iris syndrome — inform ophthalmologist before cataract surgery
Finasteride or dutasteride (5-ARI)[1]
5-alpha-reductase inhibitor
- Adult
- Finasteride 5 mg PO daily; dutasteride 0.5 mg PO daily
- Paediatric
- —
Add to alpha-blocker for prostate >30 mL or PSA >1.5; takes 6–12 months for full effect; reduces PSA by ~50% (interpret cancer screening accordingly); sexual side effects; teratogen — avoid handling crushed tablets in pregnancy
Combination alpha-blocker + 5-ARI (Combodart, Jalyn)[1]
Combination
- Adult
- Tamsulosin 0.4 mg + dutasteride 0.5 mg PO daily
- Paediatric
- —
Convenient single-pill combination; CombAT trial showed superior symptom and progression outcomes
Tadalafil 5 mg (LUTS + ED)[1]
PDE5 inhibitor
- Adult
- 5 mg PO once daily
- Paediatric
- —
Daily-dose tadalafil approved for combined LUTS and ED; do not combine with nitrates; useful when sexual function preservation prioritised
Antimuscarinic (solifenacin, tolterodine) for OAB component[1]
Muscarinic antagonist
- Adult
- Solifenacin 5–10 mg PO daily; tolterodine ER 4 mg PO daily
- Paediatric
- —
Add for OAB symptoms (urgency, frequency, nocturia) when residual urine acceptable; check PVR before adding (caution if >150 mL); dry mouth, constipation
Mirabegron (beta-3 agonist) for OAB component[1]
Beta-3 agonist
- Adult
- 25–50 mg PO daily
- Paediatric
- —
Alternative to antimuscarinic; lower dry mouth burden; BP elevation; less anticholinergic side effects
Safety-net
- Avoid sudden stopping of alpha-blocker before cataract surgery — it does not prevent floppy iris syndrome; tell your ophthalmologist about the medication[1]
- Inability to pass urine, severe lower abdominal pain or distension — same-day medical review for catheterisation[1]
- On 5-ARI: PSA halves over 6–12 months; if any rise from new nadir, investigate for prostate cancer[1]
Referral criteria
- Acute or chronic retention not relieved by trial without catheterUrology[1]
- Recurrent UTI, bladder stones, hydronephrosis, or persistent residual >300 mLUrology for surgical evaluation[1]
- Suspected prostate cancer (raised PSA, abnormal DRE, family history)Urology with multiparametric MRI prostate[1]
- Failure of medical therapy after 3–6 months at adequate doseUrology for surgical / MIST evaluation[1]
Clinical summary
Diagnosis and stepwise medical and surgical management of male lower urinary tract symptoms attributed to BPH.